19.09.2012 Views

Governance - Xstrata

Governance - Xstrata

Governance - Xstrata

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Directors’ report<br />

Results and dividend<br />

The Group’s financial results are set out in the financial information<br />

section and in the Financial review section of this report.<br />

The Board recommends a final dividend of US$0.20 per share<br />

amounting to $586 million. The total 2010 dividend is US$0.25<br />

per share or $732 million. The shareholders will be asked to approve<br />

the dividend at the Annual General Meeting on 4 May 2011, for<br />

payment on 13 May 2011 to ordinary shareholders whose names<br />

were on the register on 26 April 2011.<br />

Principal activities<br />

<strong>Xstrata</strong> is a major global diversified mining group with its<br />

headquarters in Zug, Switzerland, and has a Premium Listing on<br />

the London Stock Exchange. <strong>Xstrata</strong> also has a Secondary Listing<br />

on the SIX Swiss Exchange. Additional information on the Group’s<br />

operations is provided in the Business overview and strategy,<br />

Financial review and Operational review sections of this report.<br />

Review of the business, future developments<br />

and post balance sheet events<br />

A review of the business and the future developments of the Group<br />

is presented in the Chairman’s statement, Chief Executive’s report<br />

and the Business review from page 50 to page 95.<br />

A full description of acquisitions, disposals, and changes to Group<br />

companies undertaken during the year, including post balance sheet<br />

events, is included in the Financial review on pages 50 to 55.<br />

Corporate governance<br />

A report on corporate governance and compliance with the<br />

principles and provisions of the Combined Code on corporate<br />

governance is set out on pages 110 to 118 and forms part of this<br />

report by reference.<br />

Financial instruments<br />

The Group’s financial risk management objectives and policies, details<br />

of its financial instruments, hedging activities and its exposures to<br />

price risk, credit risk and liquidity risk are discussed on pages 50 to 55<br />

of the Financial review and in Note 37 of the Financial statements.<br />

Creditor payment policy and practice<br />

In view of the international nature of the Group’s operations there<br />

is no specific Group-wide policy in respect of payments to suppliers.<br />

Individual operating companies are responsible for agreeing terms<br />

and conditions for their business transactions and ensuring that<br />

suppliers are aware of the terms of payment. It is Group policy that<br />

payments are made in accordance with those terms, provided that<br />

all trading terms and conditions have been met by the supplier.<br />

<strong>Xstrata</strong> plc is a holding company with no business activity other than<br />

the holding of investments in the Group and therefore had no trade<br />

creditors at 31 December 2010.<br />

Health, safety, environment & community (HSEC)<br />

An overview of health, safety and environmental performance and<br />

community participation is provided throughout the Strategy section<br />

on pages 18 to 47.<br />

www.xstrata.com | 105<br />

Exploration and research and development<br />

The Group business units carry out exploration and research and<br />

development activities that are necessary to support and expand<br />

their operations.<br />

Political and charitable donations<br />

In accordance with <strong>Xstrata</strong>’s corporate social involvement (CSI) policy,<br />

no political donations were made in 2010. <strong>Xstrata</strong>’s corporate social<br />

involvement expenditure supports initiatives that benefit the<br />

communities local to the Group’s operations in the areas of health,<br />

education, sport and the arts, community development, job creation<br />

and enterprise. In 2010, <strong>Xstrata</strong> set aside over $84 million for CSI<br />

initiatives. Donations during the year to UK registered charities<br />

totalled £903,000.<br />

Employee policies and involvement<br />

The Group’s policy and performance regarding employee<br />

involvement, disabled employees, labour relations and employee<br />

share schemes are provided throughout the Strategy section on<br />

pages 18 to 47.<br />

Board of directors<br />

The directors during the year under review were Mick Davis<br />

(Chief Executive), Dr Con Fauconnier (independent non-executive),<br />

Ivan Glasenberg (non-executive), Peter Hooley (independent<br />

non-executive), Claude Lamoureux (independent non-executive),<br />

Sir Steve Robson (independent non-executive), David Rough<br />

(Deputy Chairman, Senior Independent Director and non-executive),<br />

Trevor Reid (Chief Financial Officer), Ian Strachan (independent<br />

non-executive), Willy Strothotte (Chairman and non-executive), and<br />

Santiago Zaldumbide (executive director).<br />

Further details about the directors, their skills and experience and<br />

their roles within the Group are given in the directors’ biographies<br />

on pages 102 and 103.<br />

Directors’ conflicts of interest<br />

Under section 175 of the Companies Act 2006, a director of<br />

a company must avoid a situation in which he has, or can have,<br />

a direct or indirect interest that conflicts, or possibly may conflict,<br />

with the interests of the company. The duty is not infringed if the<br />

matter has been authorised by the directors of the relevant company.<br />

Under the Act, the board of directors of the relevant company has<br />

the power to authorise potential or actual conflict situations. The<br />

Board maintains effective procedures to enable <strong>Xstrata</strong>’s directors<br />

to notify the Company of any actual or potential conflict situations<br />

and for those situations to be reviewed and, if appropriate, to be<br />

authorised by the Board, subject to conditions and for a period<br />

of one year. The Nominations Committee undertakes the role<br />

of reviewing notifications in detail and making appropriate<br />

recommendations to the Board regarding authorisation. Directors’<br />

conflict situations are reviewed annually. A register of authorisations<br />

is maintained.<br />

Overview Strategy Performance <strong>Governance</strong> Financials

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!